Citigroup

NEW YORK (GenomeWeb) – Citigroup this week initiated coverage of Cepheid with a Buy rating and a price target on its shares of $52.

NEW YORK (GenomeWeb News) – Citi Research analyst Amit Bhalla has increased his price target on Agilent Technologies' stock from $43 to $50 and has increased earnings-per-share estimates for the firm.

NEW YORK (GenomeWeb News) – Citigroup today initiated coverage of Agilent Technologies with a Buy rating and a $46 target on the company's stock.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Citigroup upgraded Life Technologies to Buy today following last week's contraction in the company's stock price.

Analyst Amit Bhalla said that trade-in revenue from customers who purchase the HiSeq 2000 platform would not be a "significant contributor," and trimmed total revenue estimates for the second quarter and full-year 2011.

The bank also placed a price target of $52 on Illumina's stock.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.